LNAI earnings analysis
What we found in LNAI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Lunai Bioworks reported a significant increase in service revenue totaling $20,942 for Q3 FY 2026, a considerable rise compared to zero revenue in the same quarter last year. Operating expenses saw a drastic decrease by approximately 65%, leading to a net loss of $2,571,394, up from a net income of $189,176 in Q3 FY 2025, reflecting ongoing challenges in profitability despite steps taken to reduce costs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Recognition Milestone
- Service revenue reached $20,942, marking a 100% increase from prior periods that recorded zero revenue.
- Major Cost Reductions
- Operating expenses fell by approximately 65% to $1,448,202, down from $4,162,492 in the previous year.
- Reduced Net Loss
- Net loss of $2,571,394 is a substantial shift from a net income of $189,176 in the same quarter last year.
- Substantial Decrease in Goodwill Impairment
- Goodwill impairment dropped to zero versus $47,614,729 in the same nine-month period last year, reflecting improved financial health.
- Improved Cash Position
- Cash and cash equivalents rose to $3,155,272, up from $92,700 in June 2025, marking a 3,304% increase.
- Significant Decrease in Total Liabilities
- Total liabilities decreased to $19,413,968 from $29,580,681, showcasing an overall reduction of $10,166,713.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial Going Concern Doubt
- The company has a working capital deficit of $15,550,002, raising substantial doubts about its ability to continue as a going concern.
- High Accumulated Losses
- Accumulated losses reached $512,014,347, emphasizing the chronic unprofitability of operations.
- Dependency on External Funding
- The company relies heavily on future funding and may not secure necessary finances, impacting operations.
What they said about what is next.
No explicit numeric guidance provided but dependency on further financing indicated.
The filing reads worse than the one before it.
What came before.
- 10-Q · February 17, 2026
- Lunai Bioworks reported a quarterly net loss of $1,799,404 (EPS $(0.08)) for the three months ended December 31, 2025, an improvement versus a $(7,252,394) loss (EPS $(0.45)) a year earlier. Operating expenses fell…
- 10-Q · November 14, 2025
- Lunai Bioworks reported GAAP net income of $2,819,021 (EPS $0.13) for the quarter ended September 30, 2025, driven largely by a $12,019,227 gain on the bankruptcy/deconsolidation of a subsidiary and other non‑operating…
- 10-Q · February 19, 2025
- Renovaro reported no revenue and continued net losses for the quarter; net loss was $(7,252,394) for the three months and $(51,464,429) for the six months ended December 31, 2024, driven primarily by a $47,614,729…
- 10-Q · November 14, 2024
- Renovaro reported a sharply wider quarterly net loss of $44,212,036 for the three months ended September 30, 2024, versus a $9,175,028 loss a year earlier, driven primarily by a $47,614,729 goodwill impairment and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LNAI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever